Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases by Rogers, J. et al.
Rapid discovery and optimization of therapeutic
antibodies against emerging infectious diseases
J. Rogers1†, R.J. Schoepp2, O. Schro ¨der1†,
T.L. Clements2, T.F. Holland1†, J.Q. Li1†,J .L i 1†,
L.M. Lewis1†, R.P. Dirmeier1, G.J. Frey1†,X .T a n 1,
K. Wong1†, G. Woodnutt1†, M. Keller1†, D.S. Reed3,
B.E. Kimmel1† and E.C. Tozer1,4
1Verenium Corporation, 4955 Directors Place, San Diego, CA 92121,
2Diagnostic Systems Division and
3Department of Animal Studies, U.S.
Army Medical Research Institute of Infectious Diseases, 1425 Porter Street,
Fort Detrick, Frederick, MD 21702, USA
4To whom correspondence should be addressed.
E-mail: eileen.tozer@yahoo.com
†No longer at Verenium
Using a comprehensive set of discovery and optimization
tools, antibodies were produced with the ability to neu-
tralize SARS coronavirus (SARS-CoV) infection in Vero
E6 cells and in animal models. These anti-SARS anti-
bodies were discovered using a novel DNA display
method, which can identify new antibodies within days.
Once neutralizing antibodies were identiﬁed, a compre-
hensive and effective means of converting the mouse
sequences to human frameworks was accomplished using
HuFRTM (human framework reassembly) technology. The
best variant (61G4) from this screen showed a 3.5–4-fold
improvement in neutralization of SARS-CoV infection in
vitro. Finally, using a complete site-saturation mutagen-
esis methodology focused on the CDR (complementarity
determining regions), a single point mutation (51E7) was
identiﬁed that improved the 80% plaque reduction
neutralization of the virus by greater than 8-fold. These
discovery and evolution strategies can be applied to any
emerging pathogen or toxin where a causative agent
is known.
Keywords: antibody discovery/humanized/optimized/SARS-
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Introduction
Emerging and re-emerging viruses that cause human diseases
are becoming of greater concern for public health. A good
example is the SARS coronavirus (SARS-CoV) virus, which
ﬁrst appeared in the human population in late 2002 and even-
tually infected  8000 people with a 10% fatality rate
(WHO, 2003). Today, the avian inﬂuenza H5N1 virus poses
a signiﬁcant threat if effective human–human transmission
develops, with the potential risk of a Spanish ﬂu-like pan-
demic (Juckett, 2006; Tellier, 2006; Thomas and
Noppenberger, 2007). The emergence of these viruses and
other biothreat agents has raised world concerns for their use
in biowarfare/bioterrorism and demonstrates the vulnerability
of society to biological threats.
Traditionally, protection from pathogens can be achieved
by either active or passive immunization. Active immuniz-
ation in which a vaccine is administered to elicit a protective
immune response is generally the desired therapeutic goal.
Unfortunately, vaccine development can be slow and expens-
ive, and in the case of biothreat agent vaccines, often fail to
have the marketability to attract commercial research and
development funding. Passive immunization where speciﬁc
antibodies are administered is a viable alternative and pro-
vides immediate and protective immunity (Casadevall,
2002). In sudden and unexpected terrorist attacks, the imme-
diacy of the protection provided from passive, protective
antibodies is especially important. Because the half-life of
human serum immunoglobulin is  20 days, passive immu-
nization could provide an effective countermeasure against
such biological weapons (Casadevall, 2002). The challenge
then lies in being able to rapidly respond to these biological
insults with the generation of speciﬁc antibodies.
Production of effective antibodies has been the subject of
extensive research and with signiﬁcant success, i.e. 20
recombinant antibodies approved as therapeutics by the FDA
as of 2006 (www.researchandmarkets.com/reports/354677).
Many organizations involved in this work either focus on the
discovery of novel antibodies and subsequently, outsource
necessary optimization efforts or vice versa. In contrast, we
utilized technology that comprehensively encompasses both
the discovery and optimization components of producing
therapeutic antibodies. In addition to eliminating potential
coordination issues between organizations, this centralized
effort can reduce timelines. Using SARS-CoV as the model
system, we have discovered, humanized, and optimized the
functional performance of novel neutralizing antibodies that
inhibit SARS infection in permissive cells and viral replica-
tion in vivo. These discovery and evolution strategies will
potentially be useful in reducing the current susceptibility to
biological threats.
Methods
Library construction
The library plasmid pBAD_ZF was constructed in several
steps using pBAD/gIII (Invitrogen, Carlsbad, CA, USA) as
the starting plasmid. A cassette containing a polynucleotide
encoding a zinc ﬁnger protein, a Flag tag, and a His tag was
inserted into the NdeI/PmeI site. Next, the zinc ﬁnger
binding domain sequence was inserted into the plasmid after
the terminator by QuikChangeTM site-directed mutagenesis
(Stratagene, La Jolla, CA, USA). The ﬁnal product vector,
pBAD_ZF, was used for cloning and expression of antibody
light and heavy chains, as described below.
Ten Balb/c mice were immunized with sucrose gradient
puriﬁed SARS virus, Centers for Disease Control and
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Thomas G. Ksiazek, Special Pathogens Branch, CDC,
Atlanta, GA, USA). Each mouse was initially dosed with
1   10
4 plaque forming units (pfu) of live virus by the intra-
peritoneal (i.p.) route on days 0, 14 and 28; followed by the
same dose of g-irradiated virus on day 47. Antibody titers on
a SARS-CoV ELISA ranged from 1:25 600 to 1:409 600.
Spleens of three mice were removed, processed through a
sterile mesh screen, washed with Dulbecco’s minimal essen-
tial medium (DMEM) with penicillin (200 IU/ml) and strep-
tomycin (200 mg/ml), and pelleted by centrifugation for
5 min at 1000 r.p.m. The cell pellet was resuspended in
DMEM containing antibiotics, 10% DMSO, and fetal bovine
serum and stored in liquid nitrogen.
RNA was extracted using TRIzol LS (Invitrogen,
Carlsbad, CA, USA) from the frozen splenocytes and cDNA
libraries were constructed using the BD SMARTTM kit (BD
Biosciences, San Jose, CA, USA). From the isolated cDNA,
light chain antibody domains were ampliﬁed using 11 VL
forward primers and a kappa reverse primer from oligo-
nucleotide sequences described in Essono et al. (2003) repre-
senting 75% of the light chains. cDNA encoding heavy
chain antibody domains was ampliﬁed using 11 VH forward
primers and six reverse primers to complement IgG1-1,
IgG1-2, IgG2a, IgG2c, IgG2c-2 and IgG3, representing 71%
of the heavy chains. A subset of the possible forward
primers was used during construction of the libraries simply
to limit the number of primers required for library
construction.
Light- and heavy-chain PCR products were fused by over-
lapping PCR. Antibody light and heavy chains were cloned
into NdeI and PacI restriction sites to form pBAD_Fab_ZF.
The cassette contained a nucleotide sequence encoding a
light chain antibody domain, a non-translated linker, and a
heavy chain antibody domain fused in-frame to the
N-terminus of the zinc ﬁnger protein. The light and heavy
chain/zinc ﬁnger proteins were expressed as separate poly-
peptide chains. The pBAD_Fab_ZF was transformed into
high efﬁciency XL1-Blue cells, plasmids were isolated, and
subsequently transformed into RosettagamiTM (DE3) compe-
tent cells (Novagen, Madison, WI, USA). A library stock of
these transformed expression host cells was stored in 10%
glycerol at 2708C.
Fab expression and cell harvest
A 50 ml aliquot of Luria-Bertani (LB) media containing
100 mg/ml carbenicillin (LB-Carb) was inoculated with
100 ml of DNA display library glycerol stock containing
 10
5 RosettagamiTM cells with pBAD_Fab_ZF. The cells
were grown with shaking at 378C for 2 h and then induced
for 3–12 h at 208C by adding 0.2% arabinose and 100 mM
ZnCl2. The induced cells were then centrifuged for 15 min at
5000 r.p.m. and the supernatant removed.
The cell pellet was resuspended in sonication buffer
(0.5 mM DTT, 0.05% Tween 20, 0.1 mg/ml salmon sperm
DNA, 10 mg/ml bovine serum albumin (BSA) or 5% milk
powder, 50 mM Na-Glutamate, 100 mM ZnCl2,1 0 m M
HEPES, pH 7.4), centrifuged, and again resuspended in
250–500 ml of sonication buffer. The cells were sonicated,
centrifuged at 48C at 16 000 r.p.m. for 10 min, and the super-
natants removed and kept on ice.
DNA display
Magnetic Dynal beads (M270 Epoxy 142.01) were labeled
using  1 mg/ml antigen (Invitrogen, Carlsbad, CA, USA).
100 ml of these beads were washed with 2  fresh sonication
buffer, added to the cell lysate described above, and mixed
by rotation for at least 45 min at room temperature.
Supernatant was removed and the beads were washed with
1 ml of sonication buffer followed by 1 ml wash buffer (soni-
cation buffer without the salmon sperm DNA). The beads
were centrifuged and all remaining buffer was removed.
Next, the beads were mixed for 5 min with 50 ml of wash
buffer plus 0.5 M NaCl (to dissociate the zinc ﬁnger–
plasmid complex) and the supernatant containing the eluted
plasmids was removed. The eluted plasmid DNA was puri-
ﬁed using Roche High Pure PCR Product Puriﬁcation Kit
(Roche Diagnostics, Manheim, Germany) and transformed
into high transformation efﬁciency DH10B or XL1-blue
Escherichia coli (E. coli) cells by heat shock at 428Cf o r
1 min. The transformed cells were grown on
LB-Carbenicillin agar plates, harvested, and the plasmid
DNA recovered using a Qiaprep Spin Miniprep Kit (Qiagen,
Valencia, CA, USA). In some cases, this plasmid DNA was
taken through another cycle of screening for additional
enrichment.
ELISA assay
For conﬁrmation of clones isolated from the discovery
screen, recovered plasmids were retransformed into the
Rosettagami strain and plated on agar. Approximately 100–
500 single colonies were selected and placed into 96-well
plates containing 0.2 ml LB-Carb. The cells were grown for
16 h, and then diluted 50–100-fold into 1 ml LB-Carb. The
diluted cells were grown and induced at middle log phase
with 0.2% arabinose and 100 mM ZnCl2 for 3–12 h at 208C.
Cells in 96-well plates were pelleted by centrifugation for
20 min at 4000 r.p.m., resuspended in 125 ml sonication
buffer, and transferred to a skirted 96-well PCR plate (Fisher
Scientiﬁc, Pittsburgh, PA, USA). The cells were sonicated
for 1 min in an ice-bath chilled microplate horn (Misonix,
Farmingdale, NY, USA). The sonicated plates were centri-
fuged at 1000 r.p.m. for 25 min and the lysate added directly
onto an antigen-coated 96-well ELISA plate.
The antigen-coated 96-well Nunc MaxiSorp plate (i.e.
spike protein at 1 mg/ml, infected cell lysate, or whole SARS
virus) was prepared by incubating 100 ml antigen/well at 48C
overnight, and then washed with 200 ml/well of PBS with
0.05% Tween 20 (PBS-T). In some cases, half of the plate
was coated with BSA to determine non-speciﬁc binding. The
plate was blocked overnight at 48C with 200 ml/well blocking
buffer (PBS-T with 5% dry milk powder or 1% BSA). The
plate was then washed four times (4 ) with PBS-T and
100 ml/well induced supernatant added for 1 h at room temp-
erature. Following 4  washes with PBS-T, 100 ml/well rat
anti-mouse kappa light chain antibody conjugated to peroxi-
dase (Invitrogen, Carlsbad, CA, USA) was added and incu-
bated for 1 h, and washed again 4  with PBS-T.
Subsequently, 100 ml of SureBlueTM TMB (KPL,
Gaithersburg, MD, USA) was incubated for 30 min at room
temperature, 1 M phosphoric acid was added to stop the reac-
tion, and absorbance at OD 450 nm measured using a
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Sunnyvale, CA, USA).
IgG production/puriﬁcation
Following sequencing, the variable domains of the heavy and
light chains were cloned in frame with their respective
human IgG1 constant domain into two separate pCEP4
expression vectors (Invitrogen, Carlsbad, CA, USA).
Antibodies were expressed by co-transfection of the vectors
into HEK293-F cells using 293fection (Invitrogen, Carlsbad,
CA, USA). Cells were grown at 200 ml scale in 1 l ﬂasks in
293 FreeStyle media at 378Ci n8 %C O 2 shaking at
130 r.p.m. for seven days.
Supernatants were harvested following a 25 min spin at
2000 g. The antibodies were puriﬁed from the supernatants
using Protein G HP columns (Amersham, Piscataway, NJ,
USA) by fast protein liquid chromatography (FPLC). The
puriﬁed IgGs were quantiﬁed in BCA protein assays, ana-
lyzed on SDS gels, and assayed for the presence of endo-
toxin using a chromogenic Limulus Amebocyte Lysate test
(Lonza, Rockland, ME, USA). If necessary, the preparations
were passed through polymyxin B gel columns (Detoxi-Gel,
Pierce 20344) for endotoxin removal.
Flow cytometric analysis
SARS-CoV spike protein (Protein Sciences, Lexington, KY,
USA) was labeled with biotin using the Biotin Protein
Labeling kit (Roche Diagnostics, Penzberg, Germany). For
testing Fabs and IgGs, 4 nM (ﬁnal concentration) spike
protein was added to various concentrations of Fabs or IgGs
in 250 ml PBS. The spike protein–antibody solution was
incubated at room temperature for 45 min and then incubated
at 48C overnight.
Vero E6 cells (ATCC, Manassas, VA, USA) were grown in
minimal essential medium containing penicillin (200 IU/ml)
and streptomycin (200 mg/ml), 2 mM L-Glutamine, 1 mM
pyruvic acid, and fetal bovine serum (Invitrogen, Carlsbad,
CA, USA) at 378Ca n d5 %C O 2 until conﬂuent. Following
trypsinization, Vero E6 cells were harvested by centrifugation
at 1000 g for 5 min, washed with PBS, and resuspended in
250 ml PBS ( 4   10
6 cells/ml). The Vero E6 cell suspen-
sion was added to 250 ml antibody–spike solution and incu-
bated at room temperature for 1 h. The samples were washed
three times by centrifugation with 500 ml PBS, resuspended in
500 ml PBS containing 200 mg/ml streptavidin–phycoerythrin
(Invitrogen, Carlsbad, CA, USA), and incubated for 1 h at
room temperature. After incubation, the cells were washed 3 
(PBS), resuspended in 500 ml PBS, and analyzed on a Dako
MoFlo ﬂow cytometer (Dako, Fort Collins, CO, USA).
Plaque reduction neutralization test
Antibodies were diluted 2-fold in Earle’s minimum essential
medium (EMEM) containing 10% fetal bovine serum and anti-
biotics [penicillin (200 IU/ml) and streptomycin (200 mg/ml)].
A polyclonal rabbit serum was used as a positive control and
diluent as a negative control with each set of samples tested.
Approximately 100 pfu SARS-CoV in 100 mlo fE M E Mm e d i a
was added to an equal volume of diluted antibodies and incu-
bated overnight at 48C. After incubation, the virus-antibody
mixtures were applied to conﬂuent monolayers of Vero cells
grown in six-well tissue culture plates, and adsorbed for 1 h at
378Ci naC O 2 incubator. Plates were overlaid with EMEM
0.6% agarose medium containing 10% fetal bovine serum and
antibiotics and incubated for 24–48 h at 378Ci naC O 2 incuba-
tor. Plaques were visualized by staining with a second EMEM
agarose overlay containing 5% fetal bovine serum, 5% neutral
red, and antibiotics. Plaques were counted 24 h after staining
and 50 and 80% plaque reduction neutralization titers were
calculated relative to the negative controls.
Identiﬁcation of framework reassembly sequences
Complementarity determining regions (CDR) in the mouse
antibody sequence were identiﬁed (http://www.bioinf.org.uk/
abs/). dsDNA CDR fragments were created by annealing syn-
thetic oligonucleotides encoding the mouse sequences.
Oligos were designed to leave single stranded overhangs on
both sides, compatible with the framework fragments.
Framework fragments were designed to represent the
sequence diversity exhibited by the ﬁrst three human frame-
work regions (FRs). Separate fragment libraries were con-
structed based on the human germline immunoglobulin
heavy and light chain variable domains (VH and VL), and
human variable domains that have been through the natural,
immunological maturation process. For each FR, several
fragments were designed to represent the diversity seen
among natural FRs. CDR 1, 2 and 3 from the best neutraliz-
ing antibody (4049Fab14) was combined with all possible
combinations of the FRs from the fragment library to gener-
ate novel VH and or VL constructs. For the kappa light
chain, the total number of possible combinations of reas-
sembled frameworks was 224 (number of unique sequences
for FR1 ¼ 7, FR2 ¼ 4, FR3 ¼ 8 and FR4 ¼ 1) and for the
heavy chains was 280 (number of unique sequences for
FR1 ¼ 7, FR2 ¼ 5, FR3 ¼ 8 and FR4 ¼ 1).
Synthesis of full-length variable domain variants
A5 0-biotinylated dsDNA hook fragment was attached to
streptavidin-coated magnetic beads. Full-length variable
domains were synthesized by ligating the pool of framework
1 to the hook, washing unbound material, ligating CDR 1,
followed by the pool of framework 2, and so on until all
fragments were added in the correct order. Full-length reas-
sembly products were separated from the beads with the
appropriate restriction enzymes and cloned into pCEP4
vectors containing a mammalian secretion signal and either
the kappa light chain constant domain or the IgG1 constant
domain. Ligation products were transformed into E. coli
(XL1Blue) and sequenced.
Eight light chains were designed and synthesized (DNA2.0,
Menlo Park, CA, USA) in addition to the reassembly library.
Each of these light chains represents one of the eight sequence
clusters identiﬁed in the bioinformatic analysis.
Gene site saturation mutagenesis
Gene site saturation mutagenesis (GSSMTM) was performed
as described previously (Kretz et al., 2004) using 32-fold
degenerate oligonucleotides to randomize each codon in the
CDR regions so that all possible amino acids would be
encoded. The mutated DNA pool was transformed into
XL1-Blue cells and all possible variants for each site were
identiﬁed by sequence analysis. After sequencing two
96-well plates (188 clones), we found that at least 16
(usually greater) of the possible 20 amino acids were rep-
resented at most positions and decided this diversity was
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required an extra 96-well plate of variants sequenced in
order to achieve at least 16 amino acid changes.
High-throughput analysis of HuFRTM and GSSMTM libraries
Following sequence analysis of the human framework
reassembly (HuFRTM) and GSSMTM libraries, the appropriate
clones were identiﬁed and arrayed into deep 96-well plates.
The cultures were grown for 36–48 h at 308C with shaking
and plasmid DNA isolated using the PerfectPrep 96-well
plasmid isolation kit (Eppendorf, Hamburg, Germany).
Using an automated robotics system, 96-well plates contain-
ing 293-C18 cells (50–80% conﬂuent) were transfected with
the plasmids and grown for ﬁve days at 378Ci n8 %C O 2.
Supernatants were harvested at ﬁve days and two ELISAs
were performed on each plate using a robotics system. One
ELISA was a functional ELISA using the spike protein as
the antigen following the protocol described above except
that the secondary antibody was an anti-human kappa anti-
body conjugated to peroxidase (Sigma, St Louis, MO, USA).
The second ELISA measured the relative amount of antibody
expressed. This ELISA was similar to the functional assay
with the exception that streptavidin-coated plates (Sigma, St
Louis, MO, USA) were used with a biotinylated anti-human
IgG (Sigma, St Louis, MO, USA) to capture the expressed
antibody on the plates.
Biacore analysis
The kinetics of the human and chimera antibodies were
tested using surface plasmon resonance technology on a
Biacore 2000. Each antibody was captured onto the sensor
surface using an anti-human IgG antibody at the desired
level of  200 RU. Binding of the SARS spike protein was
tested at 100 and 33.3 nM as the highest concentrations for
the 4049Fab14 and 2978/10 antibodies, respectively, with a
3-fold dilution series. Each sample concentration series was
tested in duplicate. Surfaces were fully regenerated with two
30 s pulses of 1/100 dilution of phosphoric acid.
Animal studies
Retired breeder Balb/c mice were split into two groups, with
one group injected i.p. with 15 mg/kg of the best optimized
antibody (2978/10) and a second group injected i.p. with a
similar dose of an irrelevant isotype-matched antibody.
Immediately following the antibody injection, mice were
challenged by aerosol exposure to SARS-CoV using a whole-
body chamber within a class III biological safety cabinet
maintained under negative pressure for 10 min. The aerosol
was created by a three-jet collison nebulizer (BGI, Inc.
Waltham, MA, USA) controlled by an automated bioaerosol
exposure system (Hartings, 2004). Aerosol concentration of
virus was determined by constant sampling of the chamber
using an all-glass impinger (AGI; Ace Glass, Vineland, NJ,
USA) with Hank’s balanced salt solution (HBSS) containing
1% fetal calf serum and 0.08% antifoam A as the collection
medium. Virus concentration in starting solutions and
all-glass impinger (AGI) was determined by plaque assay.
Determination of presented dose was calculated using
respiratory minute volume (Vm) estimates derived by
Guyton’s formula (Vm ¼ 2.10+Wb
0.75 where Wb is body
weight). Presented dose was calculated by multiplying
the total volume (Vt) of experimental atmosphere inhaled
(Vt ¼ Vm   length of exposure) by the aerosol concentration
(Ce) (presented dose ¼ Ce   Vt). The inhaled dose was
293 pfu based on the concentration of the virus in the aerosol
and the predicted volume of air that each mouse inhaled in
10 min. On day 3 following the challenge, mice were sacri-
ﬁced and the lungs removed for analysis. Lung homogenates
were tested for presence of virus by plaque assay on Vero
cells. The lower limit of detection is 0.06 pfu/g.
Results
Library construction and screening
Two libraries were constructed from the spleens of three
mice immunized with SARS-CoV. These libraries had a
complexity of 30 000 and 300 000 members and were gener-
ated by reverse transcription polymerase chain reaction using
antibody-speciﬁc primers. The smaller library was generated
for proof of principle studies and the larger was subsequently
made to increase the screening population.
Screening of these libraries was accomplished using a
novel high throughput DNA display methodology (Fig. 1).
This technique involves the intracellular expression of a Fab
fragment as a fusion protein with a zinc ﬁnger. Because the
zinc ﬁnger binds to its corresponding DNA binding domain
on the plasmid, the fusion protein binds to the DNA encod-
ing its genotype. Following cell lysis, this complex is panned
against the antigen of interest. The fusion protein–plasmid
complex was found to be extremely stable by Biacore analy-
sis (data not shown) with a half-life of  9 h at room temp-
erature. Also of note, tests were done to ensure that no
plasmid switching occurred at this time (i.e. the complex dis-
sociating and the fusion protein binding to the wrong
plasmid). Multiple separate screens were performed using
Dynal beads coated with the spike protein, whole viral iso-
lates, and infected cell lysates as antigens.
These screens resulted in hundreds of potential candidates
to the three different antigen preparations. Conﬁrmation and
prioritization of the potential hits was performed by a sand-
wich ELISA using the spike protein as the capture antigen.
Relative antibody expression levels were measured in a
second ELISA and subsequently, used to determine ‘speciﬁc
activity’ (i.e. functional ELISA/quantitative ELISA) of the
various anti-SARS Fabs. Seventy-eight Fab candidates exhib-
ited conﬁrmed binding activity to the spike protein. Figure 2
is data from one ELISA plate and demonstrates the recovery
rate of SARS-reactive antibodies from the screen was  10–
15%. Twenty-eight of these antibodies bound to the spike
protein with 3-fold or greater activity than background.
Neutralization of viral binding
All 28 candidates described above were tested for their
ability to block binding of the spike protein to Vero E6 cells,
which are known to carry the ACE-2 receptor responsible for
mediating SARS virus entry. Six of the 28 candidates inhib-
ited binding of the spike protein to Vero E6 cells (Fig. 3). Of
the six clones, three Fabs were unique following sequence
analysis with each clone represented twice. All three of these
antibodies came from experiments using the spike protein as
antigen in the discovery screen.
These three Fabs (along with six others) were converted
into a chimeric IgG1 form containing a human constant
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binding domain fusion. All the three antibodies retained their
ability to block spike protein binding to the Vero E6 cells
(data not shown).
The puriﬁed antibodies were tested in plaque reduction
neutralization tests (PRNTs) using a live SARS virus on the
permissive Vero E6 cell line. The results are summarized
in Table I and showed ﬁve antibodies exhibiting 50%
neutralization activity at concentrations ranging from 0.59 to
21 mg/ml. All three of the antibodies that had blocked spike
binding to Vero E6 cells (i.e. 4049Fab14, 3889Fab33,
3889Fab35) also showed neutralization in the PRNTs. Two
additional antibodies that had not blocked spike binding did
neutralize SARS infection, suggesting an inhibitory mechan-
ism other than direct blockage of receptor binding epitopes.
One of these antibodies, 4049Fab28, was discovered using
viral isolates as the antigen. 4049Fab14 and 3889Fab33
showed 80% neutralization at concentrations of ,0.7 and
4.75 mg/ml, respectively. 4049Fab14 exhibited the best neu-
tralization activity and was chosen for the subsequent optim-
ization studies.
Antibody humanization
With the potential for these antibodies to be used as human
therapeutics, our HuFRTM technology was used to convert
the mouse variable region sequences of the 4049Fab14 anti-
body to human antibody sequences. The random combination
of all the possible heavy and light chains results in 62 720
combinations (280   224, respectively). To limit the size of
the screen, it was divided into two parts with the heavy
chain library screened ﬁrst followed by the light chain
library. The ﬁrst screen used eight ﬁxed light chains com-
posed of the three CDRs of the mouse variable region
(4049Fab14) together with consensus sequences from the
selected pools of the four deﬁned framework families in the
variable region. These eight light chains were each paired
with a heavy chain library composed of 176 unique variants
arrayed in duplicate on four 96-well plates (88 clones per
plate) for a total of 32 ‘96-well plates’ (1408 clones). The
supernatants derived from the transfected framework library
were assayed both for functional activity (i.e. reactivity to
the SARS spike protein) and for relative antibody expression
levels (i.e. production of sufﬁcient antibody). From this
initial screen, 176 unique hits (12.5%) were chosen that had
a speciﬁc activity of 0.7 or greater when normalized to
the mouse–human chimera (i.e. 4049Fab14). Following
conﬁrmation of the hits (assayed in duplicate) using the same
two ELISA assays, the top 10 performers were chosen based
on normalized speciﬁc activity (i.e. the degree of binding
activity to the puriﬁed spike protein normalized to IgG con-
centration and further normalized to the speciﬁc activity of the
original mouse–human chimeric antibody). The 10 best per-
formers had speciﬁc activities ranging from 0.9 to 1.381
(Fig. 4).
Fig. 1. Schematic of DNA display. A Fab library is constructed using a single vector containing a Fab light chain and the heavy chain cloned in-frame with a
zinc ﬁnger DNA binding protein. The vector also contains the DNA binding site for the zinc ﬁnger. The library is transformed into a Rosettagami E coli host
and the Fab-zinc ﬁnger fusion protein is produced. It binds to the appropriate encoding plasmid, the cells are lysed, and the library screened against an antigen
bound to magnetic Dynal beads. Beads containing bound Fab are magnetically separated from unbound Fab and plasmids containing functional Fabs are eluted
from the beads.
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didates paired with the light chain library composed of 176
variants arrayed in duplicate on four 96-well plates for a total
of 40 ‘96-well plates’ (1760 clones). From this initial screen,
352 hits ( 20%) were chosen with a speciﬁc activity .1.1
when compared to the original 4049Fab14 antibody. These
hits derived from the primary screen were assayed again in
duplicate using the same ELISA assays. The top 10 perfor-
mers from this secondary screen exhibited speciﬁc activities
ranging around 1.5–2-fold (with a high of 2.8 and a low of
1.12) greater than the mouse–human chimera (Fig. 4). These
high and low values were chosen due to the very high level
of expression (1.12 value) and very low expression but rela-
tively high functional activity (2.8 value). Five of the 10
heavy chains appeared in these top light chain candidates
with one of the heavy chains (23F9) represented in ﬁve of
the clones.
These top 10 antibodies were puriﬁed and analyzed by
PRNTs using live SARS-CoV on the permissive Vero E6
cell line. The results are summarized in Fig. 4 and show that
one of the humanized clones (61G4) achieved 80% neutraliz-
ation of the SARS virus at a 3.5–4-fold lower concentration
compared to the mouse–human chimera (WT) and a second
humanized clone (61H4) was equal to WT. Clones not
shown in Fig. 4C had 80% neutralization capabilities less
than wild-type (WT) (i.e. 6.25 mg/ml). Thus, after screening
 3200 clones in duplicate, we found two humanized anti-
bodies that either maintained functional activity or showed
an enhancement of activity. The fact that some clones exhib-
ited lower neutralization activity than WT, although showing
enhanced binding to the spike protein, is not surprising, as
one should not expect a perfect correlation to exist between
the spike protein ELISA and the SARS viral neutralization
assay.
Antibody optimization
While neutralizing efﬁciency is dependent on many different
antibody-binding characteristics (e.g. epitope recognition,
ﬁne speciﬁcity, reaction rate kinetics), there is some evidence
that the afﬁnity of the antibody correlates well with its
Fig. 2. Representative ELISA data of SARS-CoV-reactive Fabs isolated by DNA display. (A) Zinc ﬁnger-Fab fusion proteins analyzed in an ELISA using the
spike protein as a capture reagent on 48 wells of a 96-well Maxisorp plates. Bovine serum albumin coated on the remaining 48 wells was used to determine
speciﬁcity of binding. (B) Relative speciﬁc activity is the functional activity from Fig. 2A normalized to the amount of fusion protein determined using an
ELISA measuring relative expression levels.
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500neutralization ability (Burton, 2002; Hudson and Souraiu,
2003; Nelson et al., 2007). With this in mind, the CDR
regions of 4049Fab14 were subjected to afﬁnity maturation
by a strategy called GSSMTM. This method produces every
possible amino acid at each site individually within the
protein or region of interest. There are 27 and 40 amino
acids in the three CDR regions of the light and heavy chains
of 4049Fab14, respectively. As this screen was performed
simultaneously with the HuFRTM screen, each of these
amino acids was individually mutated to all other possible
codons in the backbone of the mouse–human chimera.
Clones were sequenced to identify appropriate amino acid
changes and arrayed in duplicate into 96-well plates with
two amino acid positions per plate ( 20 amino acids per
position for a total of 40 clones). Thus, the total number of
plates screened for the 67 amino acids found in the CDR
regions was 34 ‘96-well plates’ ( 1350 clones). These anti-
body variants were screened in the same functional and
quantitative ELISAs as the framework reassembly screen.
From this initial screen, 330 clones ( 24%) were chosen
which exhibited a speciﬁc activity when normalized to the
mouse–human chimera  1.0. These clones derived from the
primary screen were assayed in duplicate again in the same
ELISA assays and the top 10 performers chosen. These 10
antibodies, when normalized to the mouse–human chimera,
showed speciﬁc activities ranging from 1.16 to 1.92 (Fig. 5).
The puriﬁed antibodies were subsequently analyzed in
PRNTs with two of the GSSMTM variants achieving 80%
neutralization at  3.5-fold (52G3) and .8-fold (51E7)
lower concentrations than that of the WT chimeric antibody.
For the 51E7 variant, the neutralization activity was .80%
at the lowest titer used (i.e. 0.195 mg/ml). Clones not shown
had 80% neutralization capabilities at higher concentrations
than the WT chimera, ranging from 3.12 to 12.5 mg/ml.
Our experience suggests that there is often a signiﬁcant
additive or synergistic effect on functional activity when
combining beneﬁcial single point mutations (Gray et al.,
2001; Palackal et al., 2004). In addition, we wanted the best
antibodies to have humanized frameworks. Thus, a new
library was constructed to place all combinations of the posi-
tive or neutral single point mutations into the backbone of
the framework reassembly clones. The two framework clones
used as the backbone for the library were 61G4 and 61H4.
Fig. 3. Binding of the spike protein–antibody mixture to Vero E6 cells. Vero E6 cells were analyzed by ﬂow cytometry using a bandpass ﬁlter of 580/30 with
collection of 10 000 cells. (A) Cells incubated with streptavidin–phycoerythrin only, (B) cells incubated with 4 nM spike protein and a bacterial lysate from
cells expressing an irrelevant antibody, (C) same as (B) but with an anti-spike antibody that does not block binding, (D–E) same as (B) but with three unique
anti-spike antibodies that block binding of spike to its receptor. All antibodies were added at a 12 nM concentration with the exception of (D) which wasa t
8 nM. Listed % represents the % of cells following in the deﬁned gate.
Table I. PRNT for chimeric antibodies using Vero E6 cells
Antibody clone Concentration at 50%
neutralization (mg/ml)
Concentration at 80%
neutralization (mg/ml)
4049Fab14 (1E12) ,0.7 ,0.7
3889Fab33 (2A9) 0.59 4.75
3889Fab16 2.5 .10
a
3889Fab35 (2D4) 12 .12
a
4049Fab28 21 .42
a
aIndicates highest concentration tested.
Italicized rows represent antibodies that exhibited spike-blocking activity in
the ﬂow cytometric assay.
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the same heavy chain framework clone. Four different point
mutations (51E7, 52G3, 51H8, 51E2) were chosen from the
light chain and a single mutation from the heavy chain
(49B9) (Table II). The total library size was 64 possible
combinations and it was screened on the same two ELISAs
as described above. The top 10 performers all had
 1.75-fold or better binding activity when compared to the
WT chimera (Fig. 5).
In the PRNT, all of the variants achieved 80% neutraliz-
ation of the SARS virus at concentrations equal to or lower
than the WT chimera. The best antibody (i.e. 2978/10)
achieved 80% neutralization at an 8-fold lower concentration
than WT (Fig. 5). Those variants with equal ability to the
WT antibody are not shown. To determine whether the
enhanced neutralization efﬁciency correlated with increased
afﬁnity, the kinetics of the 2978/10 and WT antibodies were
measured. A 40-fold improvement in afﬁnity was observed
for 2978/10 compared to the WT chimera (KD ¼ 0.967
versus 38.5 nM, respectively) (Table III). The 2978/10
variant contained the two mutations from the top two indi-
vidual clones (51E7 and 52G3) placed in the light chain fra-
mework exhibiting the best activity (61G4) (Table II). No
additive or synergistic effect was observed (2978/10 is some-
what less effective at neutralization than 51E7 alone), which
could be due to the small library size and/or the simul-
taneous change to just two possible human frameworks.
The 2978/10 antibody was further studied in vivo to deter-
mine its ability to inhibit viral replication in the lungs of
aged mice. Initial studies demonstrated that exposure of aged
Fig. 4. Functional activity of human framework reassembly (HuFRTM) antibody variants. (A) The top 10 antibody variants from the heavy chain library as
determined by functional spike ELISA normalized to the relative expression of antibody variant. The speciﬁc activity for each antibody was further normalized
to the wild-type (WT) control antibody (i.e. WT: chimeric antibody, 4049Fab14). (B) The top 10 antibody variants from the light chain library determined as
described in (A). Numbers within bars indicate the corresponding heavy chains. (C) Puriﬁed antibody candidates were tested in the plaque reduction
neutralization test (PRNT). The number of plaques resulting in 50 and 80% neutralization is noted. Statistical analysis at the approximate WT antibody
concentration for 80% neutralization (0.78 mg/ml) indicates better neutralization (i.e. fewer plaques) for 61G4 (P, 0.04). Duplicates of each variant were
assayed in the ELISA and PRNT experiments.
Table II. Sequences of top GSSMTM and enhanced combination library
mutations
Antibody variant Amino acid substitution Nucleotide
substitution
GSSMTM – 49B9 HC Y128M CDR3 TAC!ATG
GSSMTM – 51E2 LC A56S CDR1 GCC!TCC
GSSMTM – 51E7 LC Y116F CDR3 TAT!TTT
GSSMTM – 52G3 LC S114W CDR3 AGC!TGG
GSSMTM – 51H8 LC T119V CDR3 ACG!GTT
HuFRTM (61G4) – 2978/15 Y116F, S114W, Y128M
HuFRTM (61H4) – 2703/15 S114W, Y128M
HuFRTM (61H4) – 2992/15 A56S, Y116F, S114W,
Y128M
HuFRTM (61G4) – 2978/10 Y116F, S114W
HuFRTM (61H4) – 2703/10 S114W
HuFRTM (61H4) – 2702/10 A56S, Y116F
HuFRTM (61G4) – 2699/10 A56S, S114W
Sequences in bold indicate codons requiring multiple nucleotide
substitutions.
Table III. Surface plasmon resonance analysis
Antibody Ka Kd KD (nM)
4049Fab14 3.578(9)   10
5 0.01377(3) 38.50(7)
2978/10 4.531(4)   10
5 4.38(1)   10
24 0.967(3)
The number in parentheses is the standard error in the last signiﬁcant digit.
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in viral replication in the lungs and pathology similar to the
results reported for intranasal exposure (Roberts et al., 2005)
but at a 10-fold lower dose (data not shown). Mice were
injected with 2978/10 or an irrelevant control antibody and
then immediately challenged with aerosolized SARS. Three
days later mice were necropsied and lungs taken for viral iso-
lation, with the exception of two mice that died unexpectedly
immediately following the 2978/10 injection and SARS-CoV
challenge. At a dose of 15 mg/kg, replication of SARS-CoV
in the lung was reduced to  15 000-fold with several
animals showing no evidence of SARS virus in the lung
(Table IV).
Discussion
This work introduces a novel DNA display method for rapid
screening of functional antibodies. As with other display
technologies, this method bypasses the laborious task of
hybridoma production and perhaps more importantly, allows
access to the total diversity of antibodies found within the
mice. In fact, as all heavy chains have the chance to interact
with all light chains, this method can provide even greater
diversity than found in mice. After screening an immunized
mouse library for antibodies against the spike protein, three
antibodies were isolated that inhibited infection of
SARS-CoV in Vero E6 cells. This library was recovered
from three immunized mice that had been paired with three
additional mice immunized with the same virus on the same
schedule. The other three mice had signiﬁcantly higher
serum antibody titers against SARS-CoV and were used to
generate antibodies following the traditional hybridoma
approach. Although the analysis of the hybridomas was con-
ducted solely with the SARS virus rather than with the spike
protein alone, it is interesting to note that no neutralizing
Fig. 5. Functional activity of GSSMTM and reassembled combination antibody variants. (A) The top 10 antibody variants from the GSSMTM as determined by
functional spike ELISA normalized to the relative expression of the antibody variant. The speciﬁc activity for each antibody was normalized to the wild-type
(WT) control antibody (WT: chimeric antibody, 4049Fab14). (B) Puriﬁed antibody candidates from (A) tested in the plaque reduction neutralization test
(PRNT). The number of plaques resulting in 50 and 80% neutralization is noted. Statistical analysis at the approximate WT antibody concentration for 80%
neutralization (0.78 mg/ml) indicates better neutralization (i.e. fewer plaques) for 51E7 and 52G3 (P, 0.02 and P , 0.03, respectively). (C) Top 10 antibody
variants from the combination library (containing the best GSSMTM mutants placed in the best framework backbones) determined as described in (A). (D)
Puriﬁed antibody candidates from (C) tested in the PRNT. Data was not collected for one of the 10 variants. Statistical analysis at the WT antibody
concentration for 80% neutralization (1.56 mg/ml) indicates better neutralization (i.e. fewer plaques) for several antibodies (i.e. P, 0.02 for 2978/15, 2992/15,
2978/10, 2702/10; P, 0.03 for 2703/10; P , 0.04 for 2703/15 and P, 0.05 for 2699/10). Duplicates of each variant were assayed in the ELISA and PRNT
experiments.
Table IV. Analysis of SARS-CoV in lung homogenates of mice
Animal
no.
Control group
(pfu/g   10
5)
Animal no. 2978/10 group
(pfu/g   10
5)
1 12.83 11 0.02
2 18.30 12 0
3 35.50 13 0
4 115.00 14 0.002
5 88.33 15 0
6 23.50 16 0.003
7 8.33 17 0
8 136.60 18 0
9 8.33 19
a
10 14.00 20
a
Average 46.07 0.003
b
aAnimal died within a few hours of antibody injection and SARS-CoV
challenge.
bP , 0.008 compared to control.
Discovery and optimization of therapeutic antibodies
503antibodies were found using the hybridoma approach (data
not shown) while multiple neutralizing antibodies were
found using DNA display.
There are many protein display systems described in the
literature, generally falling into three categories: viral
display, cell surface display and DNA/RNA display (Li,
2000). Phage-based systems are among the more commonly
used methods, typically based on fusion of the protein of
interest to a coat protein expressed on the phage surface.
Despite signiﬁcant successes, there are some limitations to
this approach. For example, fusion to phage proteins or other
aspects of phage display may interfere with the binding prop-
erties of the protein of interest. As well, multi-subunit pro-
teins are more difﬁcult to screen by phage display. Finally,
phage display proteins are transported to the cell surface,
where the in vitro environment might not be suitable for
some protein–protein interactions. For ribosome display, the
limitation is that proteins are made entirely in vitro, and thus
might not have the right chaperones, necessary cofactors, or
appropriate redox state to fold properly.
The DNA display method described here combines the in
vivo production of proteins and an in vitro screen for desired
protein characteristics. The in vitro screen allows for a high-
throughput analysis of complex libraries with great diversity.
For in vivo production, we made functional Fabs in speciﬁc
E. coli redox strains that allowed the proper intracellular
environment for Fab production at sufﬁcient concentrations
to perform a screen. The Fab was produced as a fusion of a
zinc ﬁnger to the Fab heavy chain. The opposite construction
with the light chain fused to the zinc ﬁnger resulted in a
lower level of enrichment (data not shown). The heavy chain
alone is known to be insoluble (Davies and Riechmann,
1994) and thus, we postulate that the fusion with the zinc
ﬁnger, in combination with the proper oxidizing environ-
ment, could make the heavy chain soluble long enough to
pair with the light chain (the light/heavy chain binding
results in a soluble Fab). Due to the intracellular production
of the targeted protein during DNA display, broad appli-
cations for a variety of protein-based interactions are poss-
ible. One could use the method to probe any protein–protein
or protein–nucleic acid interactions in vivo, unlike a phage
display screen. As well, because the proteins are produced in
vivo, they could have access to chaperones that allow proper
folding. Furthermore, DNA display is simpler than phage
display in that there is no need to make a phage preparation
and the entire library can be screened in about half the time
( 1.5 days compared to three days).
While there are signiﬁcant beneﬁts from screening an
immunized library (e.g. higher afﬁnity antibodies due to in
vivo maturation, smaller library diversity required), anti-
bodies of mouse origin often result in a human anti-murine
antibody response (Schroff et al., 1985). To reduce undesired
immunogenicity, it is now relatively common to exchange
the mouse FRs with corresponding regions of human anti-
bodies, in essence ‘humanizing’ the antibody (Clark, 2000).
Several strategies for humanizing have been developed and
implemented. In an approach called ‘CDR grafting’ the non-
human CDRs are grafted onto a given human sequence. The
human sequence is selected either by the similarity of its fra-
mework sequences with the mouse frameworks or by the
similarity of its CDRs with the mouse’s (Hwang et al.,
2005). Unfortunately, both approaches do not guarantee that
the CDRs are presented in the same conformation as in the
WT antibody. As a consequence, a signiﬁcant drop in afﬁnity
is often observed (Hwang et al., 2005). The necessity to
identify and back-mutate crucial parental framework residues
in the humanized antibody by computer modeling is difﬁcult
and often empirical.
To overcome these limitations, a novel method for the fast
and efﬁcient humanization of antibodies was developed
called HuFRTM. In this method, the synthetic mouse CDR
fragments were ligated to pools of consensus framework
sequences to obtain full-length variable heavy and light
chain domains. The framework library sequences were
designed such that the same set of sequences can be used to
ligate to the CDR regions of any antibody in which humani-
zation is desired. A similar method to HuFRTM called frame-
work shufﬂing has recently been described by Dall’Aqua
et al. (2005). In this method, framework shufﬂing uses
sequences derived from germline sequences and the CDRs
are linked by PCR. The signiﬁcant disadvantage to this
approach is that for each antibody, a whole new set of PCR
primers needs to be designed.
Using the HuFRTM approach, we isolated one humanized
antibody (61H4) that had an equivalent ability compared to
the chimera to neutralize SARS-CoV infection in Vero E6
cells and one (61G4) that demonstrated a 3.5–4-fold
improvement in neutralization activity. Because the HuFR
method combines heavy chains with different light chains, it
generates a greater diversity of unique antibody combi-
nations; potentially increasing the likelihood of ﬁnding ben-
eﬁcial humanized scaffolds. Thus, this method provides a
comprehensive approach to humanizing antibodies without a
loss in therapeutic function.
Because of the potential for improved neutralization capa-
bility with higher afﬁnity antibodies, we attempted to
increase the afﬁnity of the top antibody variant using GSSM
methodology. However, this methodology is not limited to
afﬁnity improvements and can be used to evolve many
different properties such as speciﬁcity, protein expression,
stability, folding, etc. As it is impossible to sample all of the
sequence space within a given protein (i.e. 20
100 for a 100
amino acid protein), this methodology allows one to systema-
tically sample for ‘hot spots’ within the protein, which can
then be combined together and evaluated at a higher resol-
ution in areas of interest.
Unlike a rational approach, GSSMTM does not require any
knowledge of the structure of the protein. In contrast to the
other random approaches such as error-prone PCR, chemical
mutagenesis, and site-directed mutagenesis by sequence
overlap extension PCR, GSSMTM is comprehensive and thus
allows access to substitutions missed by these other methods.
Using this method for an enzymatic protein, it was observed
that the thermostability of a haloalkane dehalogenase was
increased by 30 000-fold when combining eight single-point
mutations discovered by GSSMTM (Gray et al., 2001). Of the
eight mutations, three required multiple base pair changes at
each codon, thus the chance of ﬁnding these mutations using
error-prone PCR would be exceedingly rare (Kretz et al.,
2004). Similarly, for the optimized antibodies presented here,
three of the ﬁve amino acid positions incorporated into the
reassembly screen required multiple base pair changes at
each position (Table II). In this study, the best single point
mutation (i.e. 51E7) resulted in .8-fold improvement in
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genesis of the entire variable region (instead of simply the
CDRs) had been done, a further improvement in neutraliz-
ation would have been observed.
For the best humanized antibody (2978/10), increased
afﬁnity correlates with an improved neutralization capacity,
however, it is not necessarily the only contributor. It is
also possible that there has been a change in the ﬁne
speciﬁcity of the antibody binding to the spike protein.
Studies with neutralizing cytomegalovirus glycoprotein
B-speciﬁc antibodies have shown that with only small
sequence changes, antibodies can demonstrate a wide variety
of neutralization capacities that do not strictly correlate with
their afﬁnities (Ohlin et al., 1996; Lantto et al., 2003; Barrios
et al., 2007). These differences in neutralization are attribu-
ted to small changes in their ﬁne speciﬁcities and are
observed even when the sequence changes are derived from
the same clonotype.
The concentrations required by these antibodies for neu-
tralization of SARS infection in Vero E6 cells compare well
with other anti-SARS antibodies reported in the literature
(Greenough et al., 2005; Sui et al., 2005; Coughlin et al.,
2007). As well, 2978/10 was shown to inhibit viral replica-
tion in the lungs of aged mice at a dose of 15 mg/kg. This
dose is similar to that required for Palivizumab, an anti-RSV
therapy currently being used in humans (Meissner and Long,
2003), demonstrating the potential of this anti-SARS anti-
body as a human therapeutic.
Given the likelihood of additional emerging pathogens as
well as the risk of bioterrorism, it is necessary to have effec-
tive tools to ﬁght these biological threats. Using the DNA
display method for discovery, the timeline for identiﬁcation
of novel speciﬁc antibodies is rapid, especially if immuniz-
ation of mice is not required. The screen itself requires  1.5
days per round and together with the initial construction of
the antibody library and conﬁrmation of candidate hits in the
ELISAs, discovery of new antibodies can be accomplished
within approximately three weeks. If optimization of the anti-
body is necessary, both the GSSMTM and HuFRTM technol-
ogy require 10–12 weeks each from the initial construction
of the library to the conﬁrmed hits. Thus, once a causative
agent of a new pathogen is identiﬁed, this collection of tech-
nologies provides a complete solution for the production of
therapeutic antibodies.
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